

August 11, 2023

To, <b>BSE Limited</b> , 25, P. J. Towers, Dalal Street, Mumbai – 400 001 <b>Ref:</b> Company Scrip Code: 532834	To, Listing Department, <b>National Stock Exchange of India Ltd.</b> , Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 <b>Ref:</b> Symbol: CAMLINFINE    Series: EQ
---	--

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting**

This has reference to our intimation dated August 1, 2023.

The Board of Directors of the Company at its meeting held today i.e. August 11, 2023, inter alia, approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2023.

A copy of the said Results along with the Limited Review Reports issued by the Statutory Auditors are enclosed herewith as Annexure 1.

The Board meeting commenced at 12:30 p.m. (IST) and concluded at 3.50 p.m. (IST).

This is for your information and record please.

Encl.: a/a

Thanking You,  
For **Camlin Fine Sciences Limited**

**Rahul Sawale**  
**Company Secretary**  
**& VP Legal**

 **Registered Office:**  
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLC075361

 +91 22 6700 1000

 +91 22 2832 4404

 corporate@camlinfo.com

 www.camlinfo.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023

(Rs. in Lakh, except per share data)

PART I	PARTICULARS	STANDALONE				CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
		30.06.2023	31.03.2023	30.06.2022	31.03.2023	30.06.2023	31.03.2023	30.06.2022	31.03.2023
		(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
1	Revenue from operations	16,111.16	21,815.94	15,543.85	78,943.57	41,960.26	42,670.83	38,377.49	1,68,156.40
2	Other income	601.25	123.83	1,273.61	2,883.18	636.75	199.62	102.57	579.93
3	<b>Total income</b>	<b>16,712.41</b>	<b>21,939.77</b>	<b>16,817.46</b>	<b>81,826.75</b>	<b>42,597.01</b>	<b>42,870.45</b>	<b>38,480.06</b>	<b>1,68,736.33</b>
4	<b>Expenses</b>								
	Cost of materials consumed	10,075.53	10,998.67	8,176.01	40,275.39	24,756.15	21,940.73	21,143.52	85,557.32
	Purchase of stock in trade	90.77	226.97	43.00	554.44	1,967.13	1,311.38	684.85	6,070.82
	Changes in inventories of finished goods/WIP/stock in trade	(3,844.63)	(1,479.65)	(389.46)	(4,260.60)	(5,145.24)	(2,153.45)	(4,014.55)	(10,304.99)
	Employee benefits expense	1,548.09	1,651.11	1,401.21	5,971.45	4,384.85	4,083.33	4,112.01	16,262.09
	Finance costs	1,204.69	1,338.06	1,558.31	5,694.24	1,022.00	978.03	1,872.89	5,850.48
	Depreciation and amortisation expense	1,179.71	1,071.70	727.75	3,282.10	1,878.03	1,793.20	1,437.20	6,251.21
	Other expenses	5,732.03	6,989.41	4,784.86	23,647.13	12,126.37	13,106.60	11,789.30	50,043.86
	<b>Total Expenses</b>	<b>15,986.19</b>	<b>20,796.27</b>	<b>16,301.68</b>	<b>75,164.15</b>	<b>40,989.29</b>	<b>41,059.82</b>	<b>37,025.22</b>	<b>1,59,730.79</b>
5	<b>Profit before exceptional items and share of profit/ (loss) of associate (3-4)</b>	<b>726.22</b>	<b>1,143.50</b>	<b>515.78</b>	<b>6,662.60</b>	<b>1,607.72</b>	<b>1,810.63</b>	<b>1,454.84</b>	<b>9,005.54</b>
6	Exceptional items (Refer Note 7)	-	-	-	-	-	967.84	-	967.84
7	<b>Profit before share of profit/ (loss) of associate (5-6)</b>	<b>726.22</b>	<b>1,143.50</b>	<b>515.78</b>	<b>6,662.60</b>	<b>1,607.72</b>	<b>842.79</b>	<b>1,454.84</b>	<b>8,037.70</b>
8	Share of profit/ (loss) of associate	-	-	-	-	-	-	-	-
9	<b>Profit before tax (7-8)</b>	<b>726.22</b>	<b>1,143.50</b>	<b>515.78</b>	<b>6,662.60</b>	<b>1,607.72</b>	<b>842.79</b>	<b>1,454.84</b>	<b>8,037.70</b>
10	<b>Tax Expenses</b>								
	- Current tax	176.32	303.10	93.63	1,392.06	401.56	426.21	743.38	2,867.78
	- Deferred tax	(28.14)	60.10	(105.33)	515.07	4.49	68.68	351.56	1,188.88
		<b>148.18</b>	<b>363.20</b>	<b>(11.70)</b>	<b>1,907.13</b>	<b>406.05</b>	<b>494.89</b>	<b>1,094.94</b>	<b>4,056.66</b>
11	<b>Profit for the period (9-10)</b>	<b>578.04</b>	<b>780.30</b>	<b>527.48</b>	<b>4,755.47</b>	<b>1,201.67</b>	<b>347.90</b>	<b>359.90</b>	<b>3,981.04</b>
12	Other comprehensive income								
A	(i) Items that will not be reclassified to profit or loss								
	Remeasurements of defined benefit plans	(10.65)	25.96	35.32	(87.44)	(10.65)	20.05	35.32	(93.35)
	(ii) Income tax relating to Items that will not be reclassified to profit or loss	3.72	(9.08)	(12.34)	30.55	3.72	(9.08)	(12.34)	30.55
B	(i) Items that will be reclassified to profit or loss								
	Exchange differences on translating the financial statements of foreign operations					366.47	683.88	(412.13)	2,095.02
	(ii) The effective portion of gain or loss on hedging instruments in a cash flow hedge	211.97	204.78	(15.42)	(13.94)	211.97	204.78	(15.42)	(13.94)
	(iii) Income tax relating to Items that will be reclassified to profit or loss	(74.07)	(71.56)	5.39	4.87	(74.07)	(71.56)	5.39	4.87
	<b>Other comprehensive income</b>	<b>130.97</b>	<b>150.10</b>	<b>12.95</b>	<b>(65.96)</b>	<b>497.44</b>	<b>828.07</b>	<b>(399.18)</b>	<b>2,023.15</b>
13	<b>Total comprehensive income for the period (11+12)</b>	<b>709.01</b>	<b>930.40</b>	<b>540.43</b>	<b>4,689.51</b>	<b>1,699.11</b>	<b>1,175.97</b>	<b>(39.28)</b>	<b>6,004.19</b>
14	<b>Profit/ (Loss) attributable to:</b>								
	(i) Owners of the Company					1,555.46	916.05	588.65	5,210.64
	(ii) Non-controlling interests					(353.79)	(568.15)	(228.75)	(1,229.60)
15	<b>Other comprehensive income attributable to:</b>								
	(i) Owners of the Company					549.35	829.15	(372.68)	2,034.40
	(ii) Non-controlling interests					(51.91)	(1.08)	(26.50)	(11.25)
16	<b>Total comprehensive income attributable to:</b>								
	(i) Owners of the Company					2,104.81	1,745.20	215.97	7,245.04
	(ii) Non-controlling interests					(405.70)	(569.23)	(255.25)	(1,240.85)
17	Paid-up Equity Share Capital (Face Value Re.1/- per share)	1,673.52	1,570.93	1,570.38	1,570.93	1,673.52	1,570.93	1,570.38	1,570.93
18	Other Equity				62,643.28				80,366.47
19	Earnings per Share (EPS) (of Re.1/- each) (not annualised)								
	Basic (Rs.)	0.36	0.51	0.43	3.18	0.96	0.59	0.47	3.45
	Diluted (Rs.)	0.35	0.50	0.42	3.14	0.94	0.58	0.46	3.41



Registered Office:

Camlin Fine Sciences Limited, 2<sup>nd</sup> Floor, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com

www.camlinfs.com

**Notes to financial results:**

- The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, as amended, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 11, 2023. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India.
- The figures for the quarter ended March 31, 2023 as reported in these results are the balancing figures between audited figures in respect of the year ended March 31, 2023 and the published year to date figures up to the end of the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subjected to audit.
- Other income / Other expense above includes net foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE				CONSOLIDATED			
	QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
	30.06.2023	31.03.2023	30.06.2022	31.03.2023	30.06.2023	31.03.2023	30.06.2022	31.03.2023
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
Exchange gain	-	-	1,157.11	2,377.32	-	-	-	-
Exchange loss	44.22	500.21	-	-	598.29	1,187.46	256.81	783.66
<b>Total Exchange gain / (loss)</b>	<b>(44.22)</b>	<b>(500.21)</b>	<b>1,157.11</b>	<b>2,377.32</b>	<b>(598.29)</b>	<b>(1,187.46)</b>	<b>(256.81)</b>	<b>(783.66)</b>

The exchange gain / (loss) shown above excludes exchange gain / (loss) on derivative contracts accounted as cash flow hedge.

- Finance costs include foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE				CONSOLIDATED			
	QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
	30.06.2023	31.03.2023	30.06.2022	31.03.2023	30.06.2023	31.03.2023	30.06.2022	31.03.2023
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
Exchange gain	137.57	-	-	-	616.28	178.68	-	-
Exchange loss	-	487.08	761.86	2,518.93	-	-	1,054.59	1,666.69
<b>Total Exchange gain / (loss)</b>	<b>137.57</b>	<b>(487.08)</b>	<b>(761.86)</b>	<b>(2,518.93)</b>	<b>616.28</b>	<b>178.68</b>	<b>(1,054.59)</b>	<b>(1,666.69)</b>

- Other income / other expense for standalone and consolidated above includes net gain on fair value changes in FCCB derivative for each reporting period as under:

Particulars	Rs. In Lakh			
	QUARTER ENDED		YEAR ENDED	
	30.06.2023	31.03.2023	30.06.2022	31.03.2023
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
Other Income	469.65	-	-	29.66
Other Expense	-	214.37	111.10	-
	<b>469.65</b>	<b>(214.37)</b>	<b>(111.10)</b>	<b>29.66</b>

- The Company has not allotted shares under ESOP scheme during the quarter ended June 30, 2023. No employee stock options have lapsed under ESOP -2018 during quarter ended June 30, 2023. No employee stock options under ESOP -2020 have lapsed during quarter ended June 30, 2023.
- Consequent to the Supreme People's Court of China's Order on alleged infringement of intellectual property used in the process for manufacturing Vanillin with respect to our JV Partner, the production of Vanillin at CFS Wanglong Flavors (Ningbo) Co., Ltd.(CFSWL) manufacturing facility in China has been stopped since February 19, 2021 till further directions of the Court. Apart from imposing of penalty of RMB 159.32 million (about USD 25 million / Rs. 18,031.84 lakh) on our JV partner, 7% of the aforesaid penalty amounting to RMB 11.15 million (about USD 1.70 million / Rs. 1,261.96 lakh) had also been levied on CFSWL. In the opinion of the management, based on the discussions with the JV Partner, the findings and allegations of the Honourable Court are not based on the facts and that the order passed by the Court is arbitrary. As a co-defendant with the JV Partner, CFSWL had preferred an application for retrial of the aforesaid order before Supreme People's Court of China which was heard in the month of October 2021, the decision thereof is awaited. Though the management is confident of favourable decision in the retrial proceedings and /or settlement between the JV partner and the litigant, it has been decided to utilise the existing CFSWL manufacturing facility for alternative use by manufacturing Heliotropin, an aromatic product which is downstream of Catechol. Based on the impairment testing of the investments and assets for alternative use, there are no indications of impairment in the value of investments, goodwill and tangible assets. Further in terms of the shareholders' agreement dated April 28, 2017 and its subsequent amendments, the Company and CFSWL are indemnified against penalty and or legal consequences emanating from the violation of IP rights including the right to recover the loss on the impairment of INR 967.84 lakh provided in FY 23 and disclosed as an exceptional item.
- On May 11, 2023, International Finance Corporation exercised its option to convert the Foreign Currency Convertible Bonds (FCCB) amounting to USD 15 million into 10,258,986 equity shares of face value of Re.1 each of the company at the conversion price of INR 105 per equity share which were allotted on May 12, 2023.. As per the provisions of IND AS 32 - Financial Instruments, the amortised value of the FCCB of INR 13,280.89 lakh and the fair value of the derivative of INR 839.38 lakh both as on May 12, 2023, have been recognised as follows:
  - INR 102.59 lakh being 10,258,986 equity shares of Re.1 each under 'Equity Share Capital',
  - INR 10,669.35 lakh being 10,258,986 equity shares of INR 104 each under 'Securities Premium Account' and
  - The balance amount of INR 1,669.57 lakh under 'Reserve on conversion of FCCB' under Other Equity,
- The Company's operations constitute a single business segment in Speciality Chemicals.
- Figures for previous periods have been reclassified / regrouped, wherever necessary. Such reclassification / regrouping, wherever done is not material.

Place: Mumbai  
Date: August 11, 2023

For Camlin Fine Sciences Limited

Ashish S. Dandekar  
Chairman & Managing Director



Registered Office:

Camlin Fine Sciences Limited, 2<sup>nd</sup> Floor, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLC075361

+91 22 6700 1000

+91 22 2832 4404

corporate@camlinfs.com

www.camlinfs.com

# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

To,  
The Board of Directors  
Camlin Fine Sciences Limited,  
G.S. Point, Plot No. VIII, C.S.T. Road,  
Private Layout Scheme, Kalina,  
Santacruz- (East), Mumbai-400098

## LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Camlin Fine Sciences Limited ("the Company"), for the quarter ended June 30, 2023 ("the Statement"). This Statement which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable other accounting principles generally accepted in India and in compliance with Regulation 33 of Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ("the Listing Regulations") is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. **Emphasis of Matter**

We draw attention to Note 7 of the Statement, relating to the decision of the Supreme People's Court of China ("Honorable Court") which has imposed penalty amounting to RMB 159.32 million i.e. INR 18,031.84 Lakhs on the JV partner of the subsidiary company and others for alleged infringement of intellectual property used in the manufacturing process. An amount of RMB 11.15 million i.e. INR 1,261.96 Lakhs which is 7% of the total penalty imposed is attributed to the subsidiary i.e. CFS Wanglong Flavors (Ningbo) Co. Ltd. As a matter of abundant legal caution, the subsidiary company has stopped the production facility till further directions of the Honorable Court. As per the terms of the shareholders' agreement dated April 28, 2017, and amendments made thereafter, the Company and its subsidiary company are



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001  
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

indemnified against penalty and/or legal consequences emanating from the violation of the IP rights. As a co-defendant with the JV Partner, the subsidiary company has preferred an application for retrial of the aforesaid order before Honorable Court which was heard in the month October 2021, the decision thereof is awaited. In the opinion of the Management, based on the above and for reasons as more fully discussed in the aforesaid note, no impairment of the investment value in or in respect of other receivables from the subsidiary company is required.


Our conclusion on the Statement is not modified in respect of the above matter.

**5. Other Matter**

The figures for the quarter ended March 31, 2023, as reported in the Statement are the balancing figures between audited figures in respect of the full financial year ended March 31, 2023 and the published year to date figures up to the third quarter of the relevant financial year. The figures up to the end of the third quarter of financial year ended March 31, 2023 had only been reviewed and not subjected to audit.

Our conclusion on the Statement is not modified in respect of the above matter.

**For KALYANIWALLA & MISTRY LLP  
CHARTERED ACCOUNTANTS  
Firm Registration Number 104607W/W100166**



**FARHAD M. BHESANIA  
PARTNER  
Membership Number 127355  
UDIN: 23127355BGWIHT3587**

Place: Mumbai  
Date: August 11, 2023

# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

To,  
The Board of Directors  
Camlin Fine Sciences Limited  
G.S. Point, Plot No. VIII, C.S.T. Road,  
Private Layout Scheme, Kalina,  
Santacruz- (East), Mumbai-400098

## LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Camlin Fine Sciences Limited ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2023 ("the Statement"), attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquires, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.  
  
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the following subsidiaries:
  - i. CFS Europe S.p.A.
  - ii. CFS Do Brasil Industria Comercio Importacao E Exportacao De Aditivos Alimenticios LTDA
  - iii. Solentus North America Inc
  - iv. CFS North America LLC
  - v. Dresen Quimica, S.A.P.I. de C.V.
  - vi. Inovel, S.A.S.
  - vii. Industrias Petrotec de Mexico S.A de C.V.
  - viii. Nuvel, S.A.C.



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001  
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

- ix. Britec, S.A.
- x. Grinel, S.R.L.
- xi. Chemolutions Chemicals Ltd.
- xii. CFS Wanglong Flavors (Ningbo) Co. Ltd.
- xiii. CFS Argentina S.A.
- xiv. CFS Chile De S.p.A
- xv. CFS Pahang Asia Pte Ltd.
- xvi. AlgalR NutraPharma Private Limited
- xvii. CFS De Mexico Blends S.A.P.I. DE C.V
- xviii. CFS PP (M) SDN. BHD.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting practices generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

#### **Emphasis of Matter**

6. We draw attention to Note 7 of the Statement, relating to the decision of the Supreme People's Court of China ("Honorable Court") which has imposed penalty amounting to RMB 159.32 million i.e. INR 18,031.84 Lakhs on the JV partner in the subsidiary company and others for alleged infringement of intellectual property used in the manufacturing process. An amount of RMB 11.15 million i.e. INR 1,261.96 Lakhs which is 7% of the total penalty imposed is attributed to the subsidiary i.e. CFS Wanglong Flavors (Ningbo) Co. Ltd. As a matter of abundant legal caution, the subsidiary company has stopped the production at facility till further directions of the Honorable Court. As per the terms of the shareholders' agreement dated April 28, 2017, and amendments made thereafter, the Company and its subsidiary company are indemnified against penalty and/or legal consequences emanating from the violation of the IP rights. As a co-defendant with the JV Partner, the subsidiary company has preferred an application for retrial of the aforesaid order before Honorable Court which was heard in the month October 2021, the decision thereof is awaited. In the opinion of the Parent Company's Management, based on the above and for reasons as more fully discussed in the aforesaid note, no impairment of cash generating unit of the said subsidiary or on goodwill on consolidation in respect of the said subsidiary company is required.

Our conclusion on the Statement is not modified in respect of the above matter.

#### **Other Matters**

7. We did not review the interim financial results of twelve subsidiaries incorporated outside India and a subsidiary in India included in the Statement, whose interim financial results reflects Group's share of total revenues of Rs. 32,891.03 Lakhs, total net profit after tax of Rs. 696.62 Lakhs and total comprehensive income of Rs. 770.60 Lakhs for the quarter ended June 30, 2023. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures



**KALYANIWALLA  
& MISTRY LLP**


included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

In respect of these subsidiaries located outside India whose interim financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their country and which has been reviewed by other auditors under generally accepted auditing standards applicable in their respective country. The Company's management has converted the interim financial results of these subsidiaries located outside India from accounting principles generally accepted in their country to accounting principles generally accepted in India (Indian Accounting Standards "Ind AS"). We have reviewed these conversion adjustments made by the Company's management. Our conclusion in so far as it relates to the amounts and disclosures included in respect of such subsidiaries located outside India is based on the report of the other auditors and the conversion adjustments made by the management of the Company and reviewed by us.

8. The Statement includes interim financial results of four subsidiaries incorporated outside India and a subsidiary in India which have not been reviewed and have been included on the basis of the Unaudited Management Accounts, whose interim financial results reflect Group's share of total revenue of Rs. 810.38 Lakhs, total net profit after tax of Rs. (234.51) Lakhs and total comprehensive income of Rs. (141.98) Lakhs for the quarter ended June 30, 2023. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.
9. The figures for the quarter ended March 31, 2023, as reported in the Statement are the balancing figures between audited figures in respect of the full financial year ended March 31, 2023 and the published year to date figures up to the third quarter of the relevant financial year. The figures up to the end of the third quarter of financial year ended March 31, 2023 had only been reviewed and not subjected to audit.

Our conclusion on the Statement is not modified in respect of the above matters.

**For KALYANIWALLA & MISTRY LLP**  
**CHARTERED ACCOUNTANTS**  
**Firm Registration Number 104607W/W100166**



**FARHAD M. BHESANIA**  
**PARTNER**  
**Membership Number 127355**  
**UDIN: 23127355BGWIHU9923**

Place: Mumbai  
Dated: August 11, 2023



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023									
									(Rs.in Lakh)
No.	PARTICULARS	STANDALONE				CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
		30.06.2023	31.03.2023	30.06.2022	31.03.2023	30.06.2023	31.03.2023	30.06.2022	31.03.2023
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Total Income from Operations	16,111.16	21,815.94	15,543.85	78,943.57	41,960.26	42,670.83	38,377.49	1,68,156.40
2	Net Profit from ordinary activities after tax	578.04	780.30	527.48	4,755.47	1,201.67	347.90	359.90	3,981.04
3	Net Profit for the period after tax and non-controlling interests (after extraordinary items)					1,555.46	916.05	588.65	5,210.64
4	Total Comprehensive Income for the period	709.01	930.40	540.43	4,689.51	1,699.11	1,175.97	(39.28)	6,004.19
5	Equity Share Capital	1,673.52	1,570.93	1,570.38	1,570.93	1,673.52	1,570.93	1,570.38	1,570.93
6	Other Equity				62,643.28				80,366.47
7	Earnings per share (before and after extraordinary items) (of Re 1/-each)								
	-Basic Rs.	0.36	0.51	0.43	3.18	0.96	0.59	0.47	3.45
	-Diluted Rs.	0.35	0.50	0.42	3.14	0.94	0.58	0.46	3.41

1 The above information is an extract of the detailed format of unaudited results for the quarter ended June 30, 2023 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter ended June 30, 2023 are available on the Company's website at [www.camlinfs.com](http://www.camlinfs.com) and the Stock Exchange websites i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com).

Place: Mumbai  
Date: August 11, 2023

For Camlin Fine Sciences Limited



Ashish S. Dandekar  
Chairman & Managing Director

